Get to know

Dr. Reddy’s Biologics

Within the enormity of healthcare, Biologics is the beacon of what is possible through science.

Bacterial Cell-derived Biosimilars

Our Biosimilars produced using bacterial systems are done through recombinant DNA technology and manufactured in a dedicated facility.

Mammalian Cell-derived Biosimilars

Our Biosimilars produced using mammalian cells are done through recombinant DNA technology and manufactured in dedicated facilities.

Key Figures

years experience in Biosimilars
team of Biologics expertise
regulatory audits
patient treated
sq. ft. of research and development laboratory
manufacturing capacity

Our Products

Our labs, our scientists, and our research – we are all rooting for a healthier world. Each biosimilar product is a testament to our belief in accessibility for all. We are invested in product innovation in the industry and believe that the best biotech companies are ones that are always thinking ahead.

Our Journey

US FDA Approved

Dr.Reddy's Biologics receives its first USFDA Approval 
Receives U.S. FDA Approval for Rituximab Biosimilar after successful Pre-License Inspection (PLI) of it's Bachupally facility conducted by U.S. FDA 

Dr. Reddy’s Biologics was established in the year 1998

Grafeel (Filgrastim) Launched 

A Glycosylated Protein used in Oncology to treat chemotherapy induced anemia.

||||2026||||
||||1998||||
||||2001||||

Explore Our Process of Excellence

Dr. Reddy's Biologics is a global leader in the growing Biosimilars industry. With seven products already marketed in a large network of countries and an extensive pipeline under development, our priority remains quality, access, and affordability. We are proud of our end-to-end capabilities that ensure we can deliver what our patients need today.

  • 1Product Development
    1

    Product Development

    Read More
  • 2Manufacturing
    2

    Manufacturing

    Read More
  • 3Clinical Development
    3

    Clinical Development

    Read More
  • 4Quality
    4

    Quality

    Read More
  • 5Logistics
    5

    Logistics

    Read More

1Product Development

Product Development  is a fully integrated, end-to-end process designed for cost optimization and superior quality. These capabilities position us to deliver high-quality Biosimilar products efficiently and effectively. 

  • Leveraging Quality by Design (QbD) principles, our robust process design ensures consistent quality from the lab to manufacturing scale.
  • Innovative formulation development, supported by digital tools, accelerates time-to-market.
  • AI-driven analytics enable precise data insights and agile decision-making.

Cell-line development

Analytical development

Process development

Formulation development

Process scale-up

2Manufacturing

Dr.Reddy's Biologics manufacturing facilities are equipped with mammalian and bacterial cell culture units, including advanced stainless steel bioreactors and India’s first single-use biotechnology platform, reducing cross-contamination risks. The facilities include fill-finish capabilities for vials and pre-filled syringes (PFS), supported by high-precision filling lines, visual inspection systems, and fully automated packaging. Backed by a $200 million investment and 350+ technical staff, Dr.Reddy's Biologics meets global quality standards with accreditations from regulatory bodies across Europe, Latin America, South East Asia and multiple international markets.

Drug Substance Manufacturing (DS)

Drug Product Manufacturing (DP)

Packaging

Our accreditations and certificates

3Clinical Development

Dr. Reddy's Biologics clinical development capabilities cover the entire gamut of biologic products, from initial healthy volunteer to human factor, device bridging and patient-based studies to post-approval to post-marketing and real-world studies. The process ensures efficacy, safety, and immunogenicity , meeting global regulatory standards. With expertise in protocol development, regulatory submissions, and clinical trial execution, Dr. Reddy's team effectively manages complex trials. The company also excels in clinical trial analysis, offering data-driven insights that guide strategic decisions. Their medical writing and publication services ensure that all findings are accurately documented and shared with the scientific community.

Clinical
Clinical
Clinical

Protocol development

Approvals for Clinical Trials

Clinical trial execution

Clinical trial analysis

Medical writing

Publication

4Quality

Dr. Reddy’s Regulatory and Quality Assurance teams uphold global compliance and the highest operational standards. With expertise in navigating complex international frameworks, they secure approvals from leading regulatory authorities. Critical Quality Attributes are rigorously monitored throughout manufacturing, ensuring consistency and continuous improvement. A centralised quality management system, supported by advanced tools like Laboratory Information Management System (LIMS) and Electronic Notebooks (ELN), guarantees data integrity and authenticity. This commitment ensures the delivery of safe, effective, and high-quality biologics to global markets.

5Logistics

A cornerstone of our business is the network, supply chain, and intuitive logistics we have built. Our commitment to access and reach is unwavering and our international distribution system and partners are a testament to that.

Storage

Supply chain - India

Supply chain - EU

Distribution

Collaboration is The Key

Explore opportunities for collaboration that serve our mutual passions for robust healthcare access and critical therapies for all.

Our News, Stories, and Insights

  • Publication
  • 21-12-2020

Safety and tolerability of Peg‑grafeel, a pegfilgrastim, for the prophylactic treatment of chemotherapy‑induced neutropenia and febrile neutropenia: A prospective, observational, postmarketing surveillance study in India

  • Publication
  • 09-10-2013

A Randomized, Multi Centre, Open-Label Study to Evaluate the Efficacy and Safety of Peg G-CSF as Compared to Grafeel in the Prophylaxis of Severe Neutropenia in Cancer Patients Receiving Cytotoxic Chemotherapy

  • Publication
  • 31-03-2025

Abstract No: 0556, ISNCON Conference 2014 A Randomized, Comparative, Open-label Clinical Trial of Darbepoetin Alfa Biosimilar for the Treatment of Anaemia in Pre-Dialysis Chronic Kidney Disease Patients

  • Publication
  • 23-04-2025

Abstract No: 0556, ISNCON Conference 2014 Efficacy and Safety of Indigenously Developed Darbepoetin Alfa in Dialysis Patients - A Randomised Study

Bricks of Biologics, appreciates the contribution and celebrates our people who are the building blocks of Dr. Reddy's Biologics.

 

Bricks of biologics in general refers to bio-bricks as genetic building blocks which are DNA sequences that can be assembled to create complex biological systems.